Recent insights regarding the molecular basis of myeloproliferative neoplasms
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jang, Mi-Ae | - |
dc.contributor.author | Choi, Chul Won | - |
dc.date.accessioned | 2021-08-11T08:39:10Z | - |
dc.date.available | 2021-08-11T08:39:10Z | - |
dc.date.issued | 2020-01 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.issn | 2005-6648 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/3265 | - |
dc.description.abstract | Myeloproliferative neoplasms (MPNs) are a heterogeneous group of clonal disorders characterized by the overproduction of mature blood cells that have an increased risk of thrombosis and progression to acute myeloid leukemia. Next-generation sequencing studies have provided key insights regarding the molecular mechanisms of MPNs. MPN driver mutations in genes associated with the JAK-STAT pathway include JAK2 V617F, JAK2 exon 12 mutations and mutations in MPL, CALR, and CSF3R. Cooperating driver genes are also frequently detected and also mutated in other myeloid neoplasms; these driver genes are involved in epigenetic methylation, messenger RNA splicing, transcription regulation, and signal transduction. In addition, other genetic factors such as germline predisposition, order of mutation acquisition, and variant allele frequency also influence disease initiation and progression. This review summarizes the current understanding of the genetic basis of MPN, and demonstrates how molecular pathophysiology can improve both our understanding of MPN heterogeneity and clinical practice. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한내과학회 | - |
dc.title | Recent insights regarding the molecular basis of myeloproliferative neoplasms | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3904/kjim.2019.317 | - |
dc.identifier.scopusid | 2-s2.0-85077896598 | - |
dc.identifier.wosid | 000505206100001 | - |
dc.identifier.bibliographicCitation | The Korean Journal of Internal Medicine, v.35, no.1, pp 1 - 11 | - |
dc.citation.title | The Korean Journal of Internal Medicine | - |
dc.citation.volume | 35 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 11 | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002538397 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | CHRONIC NEUTROPHILIC LEUKEMIA | - |
dc.subject.keywordPlus | TYROSINE KINASE JAK2 | - |
dc.subject.keywordPlus | THROMBOPOIETIN RECEPTOR | - |
dc.subject.keywordPlus | POLYCYTHEMIA-VERA | - |
dc.subject.keywordPlus | ESSENTIAL THROMBOCYTHEMIA | - |
dc.subject.keywordPlus | MUTANT CALRETICULIN | - |
dc.subject.keywordPlus | SOMATIC MUTATIONS | - |
dc.subject.keywordPlus | CLONAL HEMATOPOIESIS | - |
dc.subject.keywordPlus | ACTIVATING MUTATION | - |
dc.subject.keywordPlus | CLINICAL PHENOTYPE | - |
dc.subject.keywordAuthor | Mutation | - |
dc.subject.keywordAuthor | Thrombocythemia | - |
dc.subject.keywordAuthor | essential | - |
dc.subject.keywordAuthor | Polycythemia vera | - |
dc.subject.keywordAuthor | Primary myelofibrosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.